Zura Bio Limited Class A Ordinary Shares ZURA
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:43:59.689Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-01-15
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:48:46.988437306Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:43:58.675117+00:00
Zura Bio Limited Class A Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 3.03 | 505.2% | 58.9% | |||
| 30Δ | 3.12 | 477.4% | 54.0% | |||
| 35Δ | 3.20 | 449.5% | 49.1% | |||
| 40Δ | 1.94 | 142.5% | 51.9% | 3.29 | 421.7% | 44.2% |
| 45Δ | 1.85 | 156.2% | 49.3% | 3.37 | 393.9% | 39.3% |
| 50Δ | 1.76 | 169.9% | 46.8% | 3.46 | 366.0% | 34.4% |
| 55Δ | 1.67 | 183.5% | 44.2% | 3.55 | 338.2% | 29.5% |
| 60Δ | 1.58 | 197.2% | 41.6% | 3.63 | 310.3% | 24.6% |
| 65Δ | 1.49 | 207.2% | 38.4% | |||
| 70Δ | 1.34 | 182.9% | 29.3% | |||
| 75Δ | 1.20 | 158.6% | 20.2% | |||
| 80Δ | 1.06 | 134.3% | 11.1% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.03
- IV
- 505.2%
- B/E move
- 58.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.12
- IV
- 477.4%
- B/E move
- 54.0%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.20
- IV
- 449.5%
- B/E move
- 49.1%
40Δ
- Pseudo strike
- 1.94
- IV
- 142.5%
- B/E move
- 51.9%
- Pseudo strike
- 3.29
- IV
- 421.7%
- B/E move
- 44.2%
45Δ
- Pseudo strike
- 1.85
- IV
- 156.2%
- B/E move
- 49.3%
- Pseudo strike
- 3.37
- IV
- 393.9%
- B/E move
- 39.3%
50Δ
- Pseudo strike
- 1.76
- IV
- 169.9%
- B/E move
- 46.8%
- Pseudo strike
- 3.46
- IV
- 366.0%
- B/E move
- 34.4%
55Δ
- Pseudo strike
- 1.67
- IV
- 183.5%
- B/E move
- 44.2%
- Pseudo strike
- 3.55
- IV
- 338.2%
- B/E move
- 29.5%
60Δ
- Pseudo strike
- 1.58
- IV
- 197.2%
- B/E move
- 41.6%
- Pseudo strike
- 3.63
- IV
- 310.3%
- B/E move
- 24.6%
65Δ
- Pseudo strike
- 1.49
- IV
- 207.2%
- B/E move
- 38.4%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 1.34
- IV
- 182.9%
- B/E move
- 29.3%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 1.20
- IV
- 158.6%
- B/E move
- 20.2%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 1.06
- IV
- 134.3%
- B/E move
- 11.1%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 236.13% | |
| 257.90% |
Biotechnology
ZVRA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The…
More →ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in…
More →AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the…
More →ABCL
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
More →ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in…
More →ABOS
Description unavailable
More →